Developer docs
API playgroundTry for free, no card

Search company profiles

Knopp Biosciences

Full company profile

uuid0000wyc

Namestring
Knopp Biosciences
Legal namestring
Knopp Biosciences LLC
Websiteurl
knoppbio.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Knopp Biosciences LLC is a privately held company headquartered in Pittsburgh, Pennsylvania, that was founded in 2004 and built an 18-year track record in drug discovery targeting challenging immunological and neurological diseases. Its technology base centered on an oral small molecule discovery platform, which produced two clinical-stage assets: dexpramipexole, an oral small molecule for eosinophilic asthma, and the Kv7 platform, a set of small-molecule candidates for epilepsy and other hyperexcitability disorders.

The company has since wound down internal discovery operations and transitioned to managing a portfolio of equity securities and future product royalties. Its clinical-stage assets have been transferred to external partners: dexpramipexole is being advanced by Areteia Therapeutics, Inc., a portfolio company of Bain Capital Life Sciences, and the Kv7 platform has been acquired by Biohaven Pharmaceuticals. Knopp retains equity and royalty interests in both programs and communicates with stakeholders through a private investor portal and direct email contact.

The business model is therefore not a commercial product sale model but rather a royalty/equity participation model, with future revenue contingent on the clinical, regulatory, and commercial progress of the two partnered programs. Knopp operates with 1-10 employees and raises capital periodically, including a $14 million round led by Solas BioVentures in November 2020.

Short descriptiontext

Knopp Biosciences LLC is a privately held Pittsburgh-based company, founded in 2004, that operated an oral small molecule drug discovery platform for 18 years before transitioning to managing equity securities and future product royalties from two out-licensed clinical-stage assets in eosinophilic asthma and epilepsy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPittsburgh, United States
HQ citystring
Pittsburgh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
drug discovery services, small molecule therapeutics, clinical-stage drug development, neurological disease treatments, immunological disease treatments
Industry1 code
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biopharmaceuticals
No data
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Knopp Biosciences is a clinical-stage drug discovery and development company that has created oral small-molecule therapeutics for immunological and neurological diseases. Following out-licensing and asset sales of its clinical-stage programs (Dexpramipexole to Areteia Therapeutics and the Kv7 Platform to Biohaven Pharmaceuticals), the company now primarily manages equity securities and future product royalties from these partnered assets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Knopp Biosciences LLC is a privately held pharmaceutical company managing a portfolio of equity securities and future product royalties. Founded in 2004, the company pursued an 18-year record of drug discovery in challenging immunological and neurological diseases. The company's current portfolio includes two clinical-stage assets: dexpramipexole (an oral small molecule for eosinophilic asthma, licensed to Areteia Therapeutics) and the Kv7 platform (small-molecule treatments for epilepsy and hyperexcitability disorders, acquired by Biohaven Pharmaceuticals).

Product and service2 records
1Dexpramipexole
CategoryClinical-stage small molecule therapeutics
2Kv7 Platform
CategoryClinical-stage small molecule therapeutics
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Areteia Therapeutics, a portfolio company of Bain Capital Life Sciences, is developing dexpramipexole, Knopp's clinical-stage oral small molecule for eosinophilic asthma. Knopp retains equity and royalty interests in this asset.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Biohaven Pharmaceuticals acquired Knopp's clinical-stage Kv7 platform consisting of small-molecule treatments for epilepsy and other hyperexcitability disorders. Knopp receives consideration through equity and royalty arrangements from this transaction.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CNS-focused specialty pharma with approved and clinical-stage therapies for epilepsy and depression; comparable to Knopp in CNS mechanism-driven small-molecule development.

TypeDirect peer
Description

Specialty pharma focused on epilepsy and rare neurological disorders with an oral small-molecule asset (ganaxolone); closely comparable to Knopp's Kv7 epilepsy platform in therapeutic area and modality.

TypeDirect peer
Description

Direct partner developing Knopp's dexpramipexole in eosinophilic asthma; comparable as a clinical-stage respiratory specialty developer advancing an oral small molecule in a high-unmet-need indication.

TypeOthers
Description

Specialist in healthcare royalty and milestone-based financing; comparable in business model as an entity that monetizes future cash flows from biopharma assets similar to what Knopp now holds.

TypeDirect peer
Description

Clinical-stage neurology company with a Kv7-targeted epilepsy program (XEN1101), directly overlapping Knopp's Kv7 platform mechanism and indication focus.

TypeBroad incumbent
Description

Large pharma with approved eosinophilic asthma biologics (e.g., Nucala) and competing respiratory franchises; relevant incumbent that contextualizes the competitive environment for dexpramipexole.

TypeBroad incumbent
Description

Established CNS specialty pharma with multiple approved neurology products; comparable as a broader incumbent in the same CNS small-molecule commercial landscape Knopp's Kv7 platform targets.

TypeDirect peer
Description

Direct partner that acquired Knopp's Kv7 platform; a CNS-focused specialty pharma developing treatments for epilepsy, migraine, and other neurological disorders, making it a directly comparable CNS specialty peer.

TypeOthers
Description

Leading acquirer of biopharmaceutical royalties and milestone interests; comparable to Knopp's emerging royalty-management business model following the transition of its clinical assets.

10UCB Pharma
TypeBroad incumbent
Description

Major pharma with a leading franchise in epilepsy treatments (e.g., Keppra, Vimpat, Briviact); comparable as a broad incumbent competing in the same anti-epileptic market as Knopp's Kv7 platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Knopp Biosciences

Clinical-Stage Biopharmaceuticalsknoppbio.com

Knopp Biosciences LLC is a privately held Pittsburgh-based company, founded in 2004, that operated an oral small molecule drug discovery platform for 18 years before transitioning to managing equity securities and future product royalties from two out-licensed clinical-stage assets in eosinophilic asthma and epilepsy.

What Knopp Biosciences does

Knopp Biosciences LLC is a privately held company headquartered in Pittsburgh, Pennsylvania, that was founded in 2004 and built an 18-year track record in drug discovery targeting challenging immunological and neurological diseases. Its technology base centered on an oral small molecule discovery platform, which produced two clinical-stage assets: dexpramipexole, an oral small molecule for eosinophilic asthma, and the Kv7 platform, a set of small-molecule candidates for epilepsy and other hyperexcitability disorders.

The company has since wound down internal discovery operations and transitioned to managing a portfolio of equity securities and future product royalties. Its clinical-stage assets have been transferred to external partners: dexpramipexole is being advanced by Areteia Therapeutics, Inc., a portfolio company of Bain Capital Life Sciences, and the Kv7 platform has been acquired by Biohaven Pharmaceuticals. Knopp retains equity and royalty interests in both programs and communicates with stakeholders through a private investor portal and direct email contact.

The business model is therefore not a commercial product sale model but rather a royalty/equity participation model, with future revenue contingent on the clinical, regulatory, and commercial progress of the two partnered programs. Knopp operates with 1-10 employees and raises capital periodically, including a $14 million round led by Solas BioVentures in November 2020.

Knopp Biosciences firmographics

Firmographics
Name
Knopp Biosciences
Legal name
Knopp Biosciences LLC
Website
https://knoppbio.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
1–10 employees
Short description
Knopp Biosciences LLC is a privately held Pittsburgh-based company, founded in 2004, that operated an oral small molecule drug discovery platform for 18 years before transitioning to managing equity securities and future product royalties from two out-licensed clinical-stage assets in eosinophilic asthma and epilepsy.
Ownership category
akta.pro rank

Knopp Biosciences industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Drug discovery services
  • Small molecule therapeutics
  • Clinical-stage drug development
  • Neurological disease treatments
  • Immunological disease treatments

Where Knopp Biosciences is headquartered

Location

Headquarters

HQ city
Pittsburgh
HQ country
United States
HQ region
North America

Markets served

Knopp Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Distribution channels1 record

Marketing channels2 records

Knopp Biosciences product offering

Product offering

Core offering

Knopp Biosciences is a clinical-stage drug discovery and development company that has created oral small-molecule therapeutics for immunological and neurological diseases. Following out-licensing and asset sales of its clinical-stage programs (Dexpramipexole to Areteia Therapeutics and the Kv7 Platform to Biohaven Pharmaceuticals), the company now primarily manages equity securities and future product royalties from these partnered assets.

Product overview

Knopp Biosciences LLC is a privately held pharmaceutical company managing a portfolio of equity securities and future product royalties. Founded in 2004, the company pursued an 18-year record of drug discovery in challenging immunological and neurological diseases. The company's current portfolio includes two clinical-stage assets: dexpramipexole (an oral small molecule for eosinophilic asthma, licensed to Areteia Therapeutics) and the Kv7 platform (small-molecule treatments for epilepsy and hyperexcitability disorders, acquired by Biohaven Pharmaceuticals).

Differentiator

Problem solved

Functional benefit

Products and services

  • Dexpramipexole
  • Kv7 Platform

Companies that use Knopp Biosciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Knopp Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Knopp Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Areteia TherapeuticscoreStrategic or Co-development PartnerAreteia Therapeutics, a portfolio company of Bain Capital Life Sciences, is developing dexpramipexole, Knopp's clinical-stage oral small molecule for eosinophilic asthma. Knopp retains equity and royalty interests in this asset.
  • Biohaven PharmaceuticalscoreStrategic or Co-development PartnerBiohaven Pharmaceuticals acquired Knopp's clinical-stage Kv7 platform consisting of small-molecule treatments for epilepsy and other hyperexcitability disorders. Knopp receives consideration through equity and royalty arrangements from this transaction.

Scale indicators1 record

Recent moves5 records

Expansion highlights2 records

Knopp Biosciences competitors and assessment

Company assessment

Direct peers

  • Sage Therapeutics: CNS-focused specialty pharma with approved and clinical-stage therapies for epilepsy and depression; comparable to Knopp in CNS mechanism-driven small-molecule development.
  • Marinus Pharmaceuticals: Specialty pharma focused on epilepsy and rare neurological disorders with an oral small-molecule asset (ganaxolone); closely comparable to Knopp's Kv7 epilepsy platform in therapeutic area and modality.
  • Areteia Therapeutics: Direct partner developing Knopp's dexpramipexole in eosinophilic asthma; comparable as a clinical-stage respiratory specialty developer advancing an oral small molecule in a high-unmet-need indication.
  • Xenon Pharmaceuticals: Clinical-stage neurology company with a Kv7-targeted epilepsy program (XEN1101), directly overlapping Knopp's Kv7 platform mechanism and indication focus.
  • Biohaven Pharmaceuticals: Direct partner that acquired Knopp's Kv7 platform; a CNS-focused specialty pharma developing treatments for epilepsy, migraine, and other neurological disorders, making it a directly comparable CNS specialty peer.

Others

  • HealthCare Royalty Partners: Specialist in healthcare royalty and milestone-based financing; comparable in business model as an entity that monetizes future cash flows from biopharma assets similar to what Knopp now holds.
  • Royalty Pharma: Leading acquirer of biopharmaceutical royalties and milestone interests; comparable to Knopp's emerging royalty-management business model following the transition of its clinical assets.

Broad incumbents

  • GSK (GlaxoSmithKline): Large pharma with approved eosinophilic asthma biologics (e.g., Nucala) and competing respiratory franchises; relevant incumbent that contextualizes the competitive environment for dexpramipexole.
  • Acadia Pharmaceuticals: Established CNS specialty pharma with multiple approved neurology products; comparable as a broader incumbent in the same CNS small-molecule commercial landscape Knopp's Kv7 platform targets.
  • UCB Pharma: Major pharma with a leading franchise in epilepsy treatments (e.g., Keppra, Vimpat, Briviact); comparable as a broad incumbent competing in the same anti-epileptic market as Knopp's Kv7 platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Knopp Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Knopp Biosciences leadership team

Management profile

Number of profiles

Profiles3 records

Knopp Biosciences funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Knopp Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Knopp Biosciences

What does Knopp Biosciences do?

Knopp Biosciences is a clinical-stage drug discovery and development company that has created oral small-molecule therapeutics for immunological and neurological diseases. Following out-licensing and asset sales of its clinical-stage programs (Dexpramipexole to Areteia Therapeutics and the Kv7 Platform to Biohaven Pharmaceuticals), the company now primarily manages equity securities and future product royalties from these partnered assets.

Is Knopp Biosciences a public or private company?

Knopp Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Knopp Biosciences founded?

Knopp Biosciences was founded in 2004. It employs 1 to 10 people.

Where is Knopp Biosciences based?

Knopp Biosciences is headquartered in Pittsburgh, United States, in the North America region.

Who are Knopp Biosciences's main competitors?

Direct peers on record are Sage Therapeutics, Marinus Pharmaceuticals, Areteia Therapeutics, Xenon Pharmaceuticals and Biohaven Pharmaceuticals. Others are HealthCare Royalty Partners and Royalty Pharma. Broad incumbents are GSK (GlaxoSmithKline), Acadia Pharmaceuticals and UCB Pharma.

Does Knopp Biosciences have an API?

No public API is recorded for Knopp Biosciences.

What industry is Knopp Biosciences in?

Knopp Biosciences's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldKnopp helps create Areteia in a $350M deal to further develop an asthma drugAreteia Therapeutics, created by Knopp Biosciences and Population Health Partners, launched to develop dexpramipexole, an oral treatment for eosinophilic asthma. The company has both development and commercial rights to the drug, which has completed a phase II study. It is now entering a phase III trial.Business Wire BlogKnopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in FundingAreteia Therapeutics, created by Knopp Biosciences and Population Health Partners, launched as a clinical-stage asthma company with $350 million in Series A financing led by Bain Capital Life Sciences. The company will initiate Phase 3 trials of dexpramipexole, a first-in-class oral drug for eosinophilic asthma, in late 2022.Business Wire BlogKnopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in FundingKnopp Biosciences and Population Health Partners have launched Areteia Therapeutics, a new clinical-stage biopharmaceutical company focused on eosinophilic asthma. The entity secured up to $350 million in Series A financing led by Bain Capital Life Sciences to advance its lead candidate, dexpramipexole, into Phase 3 trials starting in late 2022.PharmiWeb.comKnopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in FundingKnopp Biosciences and Population Health Partners have launched Areteia Therapeutics, a new clinical-stage biopharmaceutical company focused on developing dexpramipexole for eosinophilic asthma. The entity secured up to $350 million in Series A financing led by Bain Capital Life Sciences to advance the drug into Phase 3 trials starting in late 2022. This funding will support the development of what is described as a potential first-in-class oral therapy for the condition.BenzingaBiohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals - Biohaven (NBiohaven Pharmaceutical Holding Company entered a global license agreement with Bristol Myers Squibb to develop and commercialize taldefgrobep alfa, a Phase 3-ready anti-myostatin adnectin for Spinal Muscular Atrophy, marking the third development asset licensed from Bristol Myers Squibb. The company also acquired Channel Biosciences LLC, a subsidiary of Knopp Biosciences LLC, along with its Kv7 channel targeting platform for $65 million in stock and $35 million in cash, with plans to advance lead asset BHV-7000 into clinical trials for focal epilepsy in 2022. Biohaven reported Q4 FY21 sales of $190.01 million, beating consensus estimates of $173.69 million, while the European Medicines Agency's CHMP adopted a positive opinion recommending approval of Biohaven and Pfizer's migraine treatment rimegepant.FierceBiotechKnopp's oral asthma drug hits primary endpoint in phase 2Knopp Biosciences' dexpramipexole met its primary endpoint in a phase 2 trial of 103 patients with moderate-to-severe eosinophilic asthma, showing significant blood eosinophil reductions. The company says the data support further development as an oral alternative to biologics like Dupixent, though secondary endpoints and asthma exacerbation data remain pending.FinSMEsKnopp Biosciences Completes Approx. $14M Series C FinancingKnopp Biosciences completed a $14M Series C financing led by Solas BioVentures, with C. David Adair joining the board. The company will use the funds for a Phase 2 trial of dexpramipexole in eosinophilic asthma, with topline data expected in Q1 2021, and first-in-human studies of KB-3061 in 2021.GlobeNewswireKnopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic AsthmaKnopp Biosciences completed enrollment in a Phase 2 trial of oral dexpramipexole for moderate-to-severe eosinophilic asthma. The randomized, double-blind, placebo-controlled study evaluates three dose levels over 12 weeks, with primary endpoint being peripheral blood eosinophil count. Top-line data is expected early in 2021.GlobeNewswireKnopp Biosciences to Present at Oppenheimer’s Private Life Sciences Company Call Series August 18Knopp Biosciences will present at Oppenheimer's Private Life Sciences Company Call Series on August 18, 2020. The company's Phase 2 dexpramipexole trial for eosinophilic asthma and preclinical Kv7 platform are highlighted. The presentation is virtual.